Report Content
Chapter 1 Methodology & Scope
1.1 Methodology
1.2 Market definitions
1.3 Market estimation & forecast parameters
1.4 Data Sources
1.4.1 Primary
1.4.2 Secondary
1.4.2.1 Paid Sources
1.4.2.2 Public Sources
Chapter 2 Executive Summary
2.1 Erdosteine (API) industry 3600 synopsis, 2021 - 2027
2.1.1 Business Trends
2.1.2 Regional trends
2.1.3 Application trends
2.1.4 End-use trends
Chapter 3 Erdosteine (API) Industry Insights
3.1 Industry segmentation
3.2 Impact of COVID-19 on the global economy
3.3 Industry ecosystem analysis
3.3.1 Vendor matrix
3.3.2 Distribution channel analysis
3.3.2.1 Distributors/ Suppliers
3.3.2.2 Contract Manufacturing
3.3.3 Impact of COVID-19 on industry value chain
3.4 Regulatory landscape
3.4.1 U.S.
3.4.2 Europe
3.4.3 Asia Pacific
3.4.3.1 Japan
3.4.3.2 Australia
3.4.3.3 India
3.5 Technology Landscape
3.5.1 Erdosteine synthesis
3.6 Cost structure analysis, 2020
3.6.1 Standard operating cost
3.6.2 Raw material cost
3.6.3 Labor cost
3.7 Component used in API manufacturing
3.8 Raw material analysis, Impact of COVID-19 on supply
3.8.1 Thioglycolic acid
3.8.2 Chloroacetyl chloride
3.8.3 Isopropyl Alcohol
3.8.4 HCL
3.8.5 Methylene Dichloride
3.9 Impact of COVID-19 on Pricing analysis
3.10 Industry impact forces
3.10.1 Growth drivers
3.10.1.1 North America: Growing trends towards cigarette smoking and exposure to tobacco smoke leading to increase in COPD
3.10.1.2 Europe: Exposure to polluted air quality leading to development of serious medical conditions like bronchitis
3.10.1.3 Asia Pacific: Pharmaceutical market expansion
3.10.2 Industry pitfalls & challenges
3.10.2.1 Limitation of the drug with certain medical condition
3.11 Growth potential analysis, 2020
3.11.1 Emerging business model
3.11.1.1 New product launch
3.11.1.2 Collaboration/ Partnership
3.11.1.3 Acquisition
3.12 Porter’s analysis
3.13 Competitive landscape, 2020
3.13.1 Company market share analysis, 2020
3.13.2 Strategy dashboard
3.13.3 Production capacity by company
3.13.4 Production capacity by region
3.13.5 Impact of COVID-19 on consumer buying behavior
3.14 PESTEL analysis
3.15 Other expectorant market overview
3.16 Overview of final product formulation for erdosteine
3.17 Innovation & sustainability
3.18 Patent landscape
3.19 Impact of COVID-19 on erdosteine demand by end-use
3.19.1 Pharmaceutical
3.19.2 CMOs
3.19.3 Research Institutes
Chapter 4 Erdosteine (API) Market, By Application
4.1 Key application trends
4.2 Bronchitis
4.2.1 Global erdosteine (API) market from bronchitis, 2016 - 2027, (Tons) (USD Million)
4.2.2 Global erdosteine (API) market from bronchitis, by region, 2016 - 2027, (Tons) (USD Million)
4.3 Chronic obstructive pulmonary disease (COPD)
4.3.1 Global erdosteine (API) market from COPD, 2016 - 2027, (Tons) (USD Million)
4.3.2 Global erdosteine (API) market from COPD, by region, 2016 - 2027, (Tons) (USD Million)
4.4 Nasopharyngitis
4.4.1 Global erdosteine (API) market from nasopharyngitis, 2016 - 2027, (Tons) (USD Million)
4.4.2 Global erdosteine (API) market from nasopharyngitis, by region, 2016 - 2027, (Tons) (USD Million)
4.5 Others
4.5.1 Global erdosteine (API) market from other application, 2016 - 2027, (Tons) (USD Million)
4.5.2 Global erdosteine (API) market from other application, by region, 2016 - 2027, (Tons) (USD Million)
Chapter 5 Erdosteine (API) Market, By End-Use
5.1 Key end-use trends
5.2 Pharmaceutical
5.2.1 Global erdosteine (API) market from pharmaceutical, 2016 - 2027, (Tons) (USD Million)
5.2.2 Global erdosteine (API) market from pharmaceutical, by region, 2016 - 2027, (Tons) (USD Million)
5.3 Contract manufacturing companies (CMO’s)
5.3.1 Global erdosteine (API) market from Contract manufacturing companies, 2016 - 2027, (Tons) (USD Million)
5.3.2 Global erdosteine (API) market from CMOs, by region, 2016 - 2027, (Tons) (USD Million)
5.4 Research Institute
5.4.1 Global erdosteine (API) market from research institute, 2016 - 2027, (Tons) (USD Million)
5.4.2 Global erdosteine (API) market from research institute, by region, 2016 - 2027, (Tons) (USD Million)
Chapter 6 Erdosteine (API) Market, By Region
6.1 Key regional trends
6.2 Latin America (LATAM)
6.2.1 LATAM erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
6.2.2 LATAM erdosteine (API) market, by application, 2016 - 2027, (Tons) (USD Million)
6.2.3 LATAM erdosteine (API) market, by end-use, 2016 - 2027, (Tons) (USD Million)
6.2.4 Brazil
6.2.4.1 Brazil erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
6.2.4.2 Brazil erdosteine (API) market, by application, 2016 - 2027, (Tons) (USD Million)
6.2.4.3 Brazil erdosteine (API) market, by end-use, 2016 - 2027, (Tons) (USD Million)
6.3 Middle East & Africa (MEA)
6.3.1 MEA erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
6.3.2 MEA erdosteine (API) market, by application, 2016 - 2027, (Tons) (USD Million)
6.3.3 MEA erdosteine (API) market, by end-use, 2016 - 2027, (Tons) (USD Million)
6.3.4 Saudi Arabia
6.3.4.1 Saudi Arabia erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
6.3.4.2 Saudi Arabia erdosteine (API) market, by application, 2016 - 2027, (Tons) (USD Million)
6.3.4.3 Saudi Arabia erdosteine (API) market, by end-use, 2016 - 2027, (Tons) (USD Million)
6.3.5 South Africa
6.3.5.1 South Africa erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
6.3.5.2 South Africa erdosteine (API) market, by application, 2016 - 2027, (Tons) (USD Million)
6.3.5.3 South Africa erdosteine (API) market, by end-use, 2016 - 2027, (Tons) (USD Million)
6.3.6 UAE
6.3.6.1 UAE erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
6.3.6.2 UAE erdosteine (API) market, by application, 2016 - 2027, (Tons) (USD Million)
6.3.6.3 UAE erdosteine (API) market, by end-use, 2016 - 2027, (Tons) (USD Million)
Chapter 7 Company Profiles
7.1 Recipharm AB
7.1.1 Business Overview
7.1.2 Financial Data
7.1.3 Product Landscape
7.1.4 SWOT Analysis
7.1.5 Strategic Outlook
7.2 Taj Pharmaceuticals Limited
7.2.1 Business Overview
7.2.2 Financial Data
7.2.3 Product Landscape
7.2.4 SWOT Analysis
7.3 Wuhan Hezhong Bio-Chemical Manufacture Co., Ltd.
7.3.1 Business Overview
7.3.2 Financial Data
7.3.3 Product Landscape
7.3.4 SWOT Analysis
7.4 Delta Finochem Pvt. Ltd.
7.4.1 Business Overview
7.4.2 Financial Data
7.4.3 Product Landscape
7.4.4 SWOT Analysis
7.5 Alitair Pharmaceuticals, Inc.
7.5.1 Business Overview
7.5.2 Financial Data
7.5.3 Product Landscape
7.5.4 SWOT Analysis
7.6 Salvavidas Pharmaceutical Private Limited
7.6.1 Business Overview
7.6.2 Financial Data
7.6.3 Product Landscape
7.6.4 SWOT Analysis
7.7 Zhejiang Kangle Pharmaceutical Co., Ltd.
7.7.1 Business Overview
7.7.2 Financial Data
7.7.3 Product Landscape
7.7.4 SWOT Analysis
7.8 Wuhan Yuancheng Pharmaceutical
7.8.1 Business Overview
7.8.2 Financial Data
7.8.3 Product Landscape
7.8.4 SWOT Analysis
7.9 Hanmi Pharmaceuticals Co., Ltd.
7.9.1 Business Overview
7.9.2 Financial Data
7.9.3 Product Landscape
7.9.4 SWOT Analysis
7.10 Shandong Luoxin Pharmaceutical
7.10.1 Business Overview
7.10.2 Financial Data
7.10.3 Product Landscape
7.10.4 SWOT Analysis
7.11 Asmoh Laboratories Ltd.
7.11.1 Business Overview
7.11.2 Financial Data
7.11.3 Product Landscape
7.11.4 SWOT Analysis
7.12 Hikma Pharmaceuticals
7.12.1 Business Overview
7.12.2 Financial Data
7.12.3 Product Landscape
7.12.4 SWOT Analysis
7.13 Jigs Chemical
7.13.1 Business Overview
7.13.2 Financial Data
7.13.3 Product Landscape
7.13.4 SWOT Analysis
